HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pseudoephedrine 2006 Sales To Decline 35%, Perrigo Projects

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's fiscal 2006 pseudoephedrine sales will decrease 35% to the $110 mil. to $120 mil. range, the company projected during a 2005 year-end and fourth quarter analysts call Sept. 7

You may also be interested in...

Perrigo’s Full Range Of Pseudoephedrine Stand-Ins Must Wait For Next Year

Perrigo will not have a complete phenylephrine portfolio available to replace pseudoephedrine products until next year's cough/cold season, the company said during a fiscal 2006 first-quarter earnings call

Phenylephrine Products Proliferate Due To Pseudoephedrine Restrictions

The growing trend of limiting pseudoephedrine accessibility in stores is driving an expanding market for nasal decongestant alternatives containing phenylephrine

Perrigo Moves In On Major Generic Firms With Agis Acquisition

Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts